Hematologic Malignancy
Lymphoid Leukemia
CI-CAN-00001101Explore in graph →
Hematologic827 active trials20 approved drugs95 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001101Explore in graph →
Clinical trials
3,262 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (489)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02991898 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | terminated | Phase 2 | 3 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 29, 2020 | clinicaltrials |
| NCT02767934 | Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia | terminated | Phase 2 | 12 | University of WashingtonOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT00983528 | Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 6 | University of California, San DiegoOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT01003769 | Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia | terminated | Phase 1 / Phase 2 | 5 | Mayo ClinicOTHER | 1 | Jun 16, 2020 | clinicaltrials |
| NCT01796470 | Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | terminated | Phase 2 | 66 | Gilead SciencesINDUSTRY | 1 | Jun 2, 2020 | clinicaltrials |
| NCT02535364 | Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)(ROCKET) | terminated | Phase 2 | 82 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 1 | May 4, 2020 | clinicaltrials |
| NCT02349178 | Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT | terminated | Phase 2 | 6 | Medical College of WisconsinOTHER | 1 | Mar 9, 2020 | clinicaltrials |
| NCT01629511 | Allogeneic Stem Cell Transplant for CLL | terminated | Phase 1 / Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 24, 2020 | clinicaltrials |
| NCT00899431 | Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT02404220 | Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) | terminated | Phase 1 / Phase 2 | 30 | Gilead SciencesINDUSTRY | 3 | Jan 2, 2020 | clinicaltrials |
| NCT02557516 | Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL | terminated | Phase 1 / Phase 2 | 22 | Innate PharmaINDUSTRY | 1 | Dec 17, 2019 | clinicaltrials |
| NCT03195010 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia | terminated | Phase 2 | 4 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT01747499 | Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation | terminated | Phase 1 / Phase 2 | 54 | Washington University School of MedicineOTHER | 1 | Oct 16, 2019 | clinicaltrials |
| NCT00276159 | Study of Immune Response Modifier in the Treatment of Hematologic Malignancies | terminated | Phase 2 | 6 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT01090414 | An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study | terminated | Phase 1 / Phase 2 | 202 | Gilead SciencesINDUSTRY | 1 | Aug 28, 2019 | clinicaltrials |
| NCT00949988 | A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia(BMS-CA180105) | terminated | Phase 1 / Phase 2 | 3 | University of California, San DiegoOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT02535806 | Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults | terminated | Phase 2 | 2 | Children's Mercy Hospital Kansas CityOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT02518750 | Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma | terminated | Phase 2 | 3 | St. Jude Children's Research HospitalOTHER | 1 | Apr 3, 2019 | clinicaltrials |
| NCT00648739 | Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM | terminated | Phase 1 / Phase 2 | 26 | Alexion Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01403246 | Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 1 / Phase 2 | 9 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT01203930 | A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL | terminated | Phase 2 | 105 | Gilead SciencesINDUSTRY | 1 | Nov 16, 2018 | clinicaltrials |
| NCT00946023 | Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab | terminated | Phase 2 | 135 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 27, 2018 | clinicaltrials |
| NCT01037764 | Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (ALL)(AHCTALL) | terminated | Phase 2 | 100 | Asan Medical CenterOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT01745913 | Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies | terminated | Phase 2 | 2 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 11, 2018 | clinicaltrials |
| NCT01050764 | Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | terminated | Phase 1 / Phase 2 | 10 | Everett MeyerOTHER | 1 | Jun 27, 2018 | clinicaltrials |
| NCT01195480 | CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL)(CD19TPALL) | terminated | Phase 1 / Phase 2 | 29 | University College, LondonOTHER | 2 | May 17, 2018 | clinicaltrials |
| NCT00984165 | Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation | terminated | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 2, 2018 | clinicaltrials |
| NCT02877082 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients | terminated | Phase 2 | 5 | Emory UniversityOTHER | 1 | Apr 30, 2018 | clinicaltrials |
| NCT01612988 | Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL(BOMP) | terminated | Phase 2 | 74 | French Innovative Leukemia OrganisationOTHER | 1 | Apr 27, 2018 | clinicaltrials |
| NCT00593554 | Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies | terminated | Phase 2 | 9 | Sherif S. FaragOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT02419755 | Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies | terminated | Phase 2 | 12 | St. Jude Children's Research HospitalOTHER | 1 | Mar 7, 2018 | clinicaltrials |
| NCT01685021 | Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL) | terminated | Phase 2 | 22 | MorphoSys AGINDUSTRY | 1 | Feb 22, 2018 | clinicaltrials |
| NCT01446900 | R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma | terminated | Phase 2 | 25 | European Institute of OncologyOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT01564277 | Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies | terminated | Phase 2 | 24 | Roswell Park Cancer InstituteOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT01312818 | Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) | terminated | Phase 2 | 2 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT01383447 | Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2017 | clinicaltrials |
| NCT00496132 | A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | terminated | Phase 1 / Phase 2 | 16 | Genentech, Inc.INDUSTRY | 0 | Jul 2, 2017 | clinicaltrials |
| NCT02259348 | Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation | terminated | Phase 2 | 12 | St. Jude Children's Research HospitalOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT01173679 | Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL | terminated | Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | Apr 14, 2017 | clinicaltrials |
| NCT00596336 | Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients(CLLIFVAC) | terminated | Phase 2 | 24 | The Royal Bournemouth HospitalOTHER | 1 | Apr 12, 2017 | clinicaltrials |
| NCT02200380 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | terminated | Phase 2 | 36 | Celldex TherapeuticsINDUSTRY | 1 | Apr 7, 2017 | clinicaltrials |
| NCT02227108 | Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma | terminated | Phase 2 | 37 | MedImmune LLCINDUSTRY | 8 | Apr 6, 2017 | clinicaltrials |
| NCT00360776 | Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2017 | clinicaltrials |
| NCT01944943 | Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia(VISMOLY) | terminated | Phase 2 | 31 | The Lymphoma Academic Research OrganisationOTHER | 1 | Mar 13, 2017 | clinicaltrials |
| NCT01621477 | T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant | terminated | Phase 2 | 34 | St. Jude Children's Research HospitalOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT02129062 | Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia | terminated | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2017 | clinicaltrials |
| NCT02086591 | A Phase II Study of Doxycycline in Relapsed NHL | terminated | Phase 2 | 7 | University of RochesterOTHER | 1 | Dec 22, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Sep 29, 2020source: clinicaltrials